ABSTRACT Aim: Toexploretheattitudes, perceptions and concernsamong decision makers about equity of access to high-cost drugs in public hospitals. Method: 25 in-depth. semi-structured interviews wereconducted with senior hospital administrators, directors of pharmacy and senior medical doctors. Topics included the decision-making process andassociated problems, andsolutions to issues ofaccess to high-cost drugs. Interviews were audiotaped, transcribed verbatimand thematically analysed. Results: Healthcare funding models wereperceived asobstacles to equity of access to high-cost drugs. Participants were concerned that there were inequities in decisions for individual patients according to public or private sector status. Tertiary public hospitals were seen to be at the 'cutting edge' and therefore were required to fund new and expensive drugs. This meant prioritising between patient groups and individuals. Participants had difficulty in identifying solutions. They suggested that ethical principlesshould be considered in addition to safety, efficacy and cost. Most wanted a transparent, accountable, evidence-based decision-making process. Conclusion: Decision makers were concemed about equity of access to high-cost drugs in public hospitals. They were also concerned about processes for decision making and the outcomes of these decisions. J Pharm Pract Res 2005; I: 18-20.
INTRODUCTION
Australians have access to medicines through different schemes. The Pharmaceutical Benefits Scheme (PBS), funded by the federal government, subsidises drugs prescribed in the community.' Private hospitals, as well as some public hospitals, have implemented the PBS as a •funding mechanism for outpatient and discharge drugs.' Pharmaceuticals supplied by public hospitals are funded primarily by the state-based hospital funding.' Thc clinical status of an inpatient differs from non-hospitalised patients-the illness is likely to be 1110re acute and other issues can affect access to medicines."
Funding for public hospitals is given to the states and territories by the federal government and this represents the largest single component of health expenditure.' Pharmaceuticals represent one of the highest costs within this category. ' How do hospitals deal with capped budgets and scarce resources? Multidisciplinary drug and therapeutics committees (DTCs) address cost priorities and aim to ensure quality use of medicines." Analysis of drug use suggests that DTCs have become more involved in cost containment and predicting budgetary needs." However, the decisionmaking process is a complex task and there are frequent additions of innovative, high-cost drugs. Economic, ethical and legal aspects may be considered, as well as the clinical and science-based evidence for drug use.! Expending resources for the benefit of some patients by depriving others is challenged as unethical.v'" The appropriate decision-making process is described as transparent, allowing fair allocation of resources to achieve the greatest benefit for patients." High-cost drugs, which may be defined through a number of mechanisms, may also be associated with low levels of evidence for the specified indication, and are often for 'off-label' use.'! Recognition of these issues does not easily translate to day-to-day management of drug access issues for individuals, institutions and policy makers.
Decisions are not based on financial cost alone, as social, legal and ethical aspects may play significant roles. Published reports have focused on different mechanisms of rationing and principles such as distributive justice.'!'!' Limited work has been conducted regarding use and funding of high-cost drugs in public hospitals. There are no published data on attitudes and concerns regarding access to high-cost drugs.
The aim of this study was to explore the attitudes, perceptions and concerns among decision makers about equity of access to high-cost drugs in public hospitals. This study is part of a larger research program investigating attitudes, perceptions and concerns of the community. Our specific objectives were to:
investigate the understanding of decision makers about high-cost drugs; investigate their perceptions, concerns and attitudes regarding the use of high-cost drugs; investigate current problems and possible solutions; investigate the criteria currently used to allocate resources to high-cost drugs; and explore the role of economic evaluation (and other data) in the decision-making process.
METHOD
Qualitative techniques were used for data collection and analysis. In-depth, semi-structured interviews were conducted between August 2003 and April 2004. All interviews were conducted by the same researcher and were of about 35 minutes duration. A purposive sample of key decision makers within the Sydney Area Health Service was identified. This included senior hospital administrators, directors of phannacy and senior medical doctors. A letter of invitation which outlined the objectives of the study was sent and a reminder letter was sent if no response W3S obtained within four weeks. A 'patient information' statement and a consent form were provided.
Interviews were audiotaped and transcribed verbatim. When new themcs were no longer occurring data collection was considered complete. The data were coded and analysed through the strategies of grounded theory. This is a standard technique used to establish a theoretical framework from collected data.
The characteristics of the participants, including age, gender, position, organisation and education background were recorded. Data were analysed using the Statistical Package for the Social Sciences (version 10).
This study was approved by the Human Research Ethics Committees of The University of Sydney and St Vincent's Hospital, Sydney and endorsed by the Chief Executive Officer of the Sydney Area Health Service.
RESULTS
Thirty-four people were invited to participate (Table I) and 25 semi-structured interviews were conducted. One participant declined to be audio taped and another was interviewed twice to clarify previous answers. Some respondents thought that public hospitals had to be at the 'cutting edge' and therefore were required to fund new, expensive drugs. A major concern for respondents was that, as a consequence, this meant prioritising between patient groups and individual cases.
So, by and large, teaching hospitals are where new and expensive therapies are used first to the utmost degree of good. Why is one patient group more important than another patient group and how do we decide which drugs should be available to each patient?
The majority of participants identified problems but had difficulty in identifying solutions. Some perceived that having a single body to fund pharmaceuticals would overcome the problems. 
Allocating Resources
Participants described criteria such as safety, effectiveness, efficacy and cost. Although it seemed like cost was the main criteria used by them it was perceived unethical to consider it as the sole driver for the decision.
A utilitarian goal was in mind-'the greatest good for the greatest number'. 
DISCUSSION
Despite many allusions to cost of health care there are no generally accepted definitions of high-cost drugs. This may be important in the interpretation of data and development of policy.!':" In this study, participants unanimously defined high-cost drugs as those which could have an impact on capped and limited budget holdings. Similar definitions have been previously described. IS They were principally concerned with those with a high acquisition cost and a low volume of usage.
Dealing with high-cost drugs was considered difficult for a number of reasons. These included the complex healthcnre systems, federal government and state as well as public and private systems.v':'? A single funding system was seen by some as a way to overcome the previous problems." However, participants achieved no consensus and other approaches were described.
As expected, cost was described as a major criterion when deciding if a high-cost drug should be available at a public hospital. Participants acknowledged that there was rationing of resources and they had difficulties describing how this should be achieved. There was a utilitarian viewpoint expressed where they wanted to achieve 'greatest good for the greatest number'. Phermacoeconomic data were not being used in the decision-making process-lack of expertise and knowledge were identified as barriers. Similar results were obtained when exploring the role of economic evaluation for health services." Biased information and lack of phannacoeconomic analysis conducted from the hospital's viewpoint were also identified as barriers to usc.
Qualitative research is not intended to produce results which can be generalised. It allows the exploration of people's views." .In this study a description of attitudes, perceptions and concerns among decision makers about access to high-cost drugs has been provided.
Limited work has been conducted on the use and funding of high-cost drugs in public hospitals. It is important to evaluate how individual perceptions may influence and assist in the decision-making process. Understanding the role of these perceptions in decision making will assist in future management of high-cost drugs.
